Guidance for the procurement of COVID-19 convalescent plasma: differences between high- and low-middle-income countries

摘要

Background and objectives COVID-19 convalescent plasma (CCP) has been used, predominantly in high-income countries (HICs) to treat COVID-19; available data suggest the safety and efficacy of use. We sought to develop guidance for procurement and use of CCP, particularly in low- and middle-income countries (LMICs) for which data are lacking.